We performed molecular and cytogenetic analyses of bone marrow aspirates from 16 different adult de novo AML patients to identify candidates for the study of KMT2A-rearranged gene fusions as a primary screening (Table 1). This evidence concerns the gene KMT2A and acute myeloid leukemia.